source
- Viking Therapeutics jumps 24% after Phase 1 obesity data, Longeveron falls 64% on mid-stage setbackIn September biotech stocks showed wide swings, with Viking Therapeutics gaining 24% and Longeveron dropping 64% as investors reacted to clinical data and trial setbacks. Viking reported Phase 1 r…
- Biogen's litifilimab shows clear or almost clear skin in cutaneous lupus after one yearBiogen reported that its experimental antibody litifilimab produced clear or almost clear skin in patients with cutaneous lupus erythematosus after one year of treatment in a mid‑stage study. The r…